OncoMatch/Clinical Trials/NCT07099898
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Is NCT07099898 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including GSK5764227 and Topotecan for neoplasms, lung.
Treatment: GSK5764227 · Topotecan — "In this study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving GSK5764227 and the other receiving topotecan."
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IV
Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). Has at least 1 target lesion per RECIST 1.1.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — systemic
Has received 1 prior platinum-based systemic therapy with a PD-(L)1 inhibitor with at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression
Must have received: anti-PD-1/PD-L1 therapy — systemic
Has received 1 prior platinum-based systemic therapy with a PD-(L)1 inhibitor with at least 2 cycles of therapy and a chemotherapy free-interval of >30 days, with documented progression
Cannot have received: antibody-drug conjugate
Exception: with a Topoisomerase-1 (TOPO1)-inhibitor payload
Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload
Cannot have received: B7-H3 targeted therapy
Has received any prior therapy with ... treatments targeting B7-H3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify